PD-1抑制剂-话题@MedSci

#PD-1抑制剂#

52篇内容 | 2927人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1278961, encodeId=b12512e896134, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=J Immunother Cancer：PD-1抑制剂联合化疗新辅助治疗可切除食管鳞状细胞癌患者的疗效, objectType=article, longId=293994, objectId=aefe293994fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aefe293994fa, replyNumber=0, likeNumber=76, createdTime=2022-01-16, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aefe293994fa, moduleTitle=J Immunother Cancer：PD-1抑制剂联合化疗新辅助治疗可切除食管鳞状细胞癌患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aefe293994fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278959, encodeId=3f6712e8959eb, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=STTT：国内多中心研究ORIENT-4证实PD-1抑制剂sintilimab（信迪利单抗）对有复发/难治性结外NK/T细胞淋巴瘤（r/r ENKTL）患者有效且耐受性良好, objectType=article, longId=293110, objectId=00a32931103c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00a32931103c, replyNumber=0, likeNumber=70, createdTime=2021-12-31, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00a32931103c, moduleTitle=STTT：国内多中心研究ORIENT-4证实PD-1抑制剂sintilimab（信迪利单抗）对有复发/难治性结外NK/T细胞淋巴瘤（r/r ENKTL）患者有效且耐受性良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=00a32931103c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278960, encodeId=65b012e89609e, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=Signal Transduct Target Ther：PD-1抑制剂Toripalimab（特瑞普利单抗）联合化疗二线治疗晚期EGFR突变NSCLC一线TKI进展后显示良好抗肿瘤疗效和可控安全性, objectType=article, longId=293109, objectId=d234293109ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d234293109ad, replyNumber=0, likeNumber=92, createdTime=2021-12-31, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d234293109ad, moduleTitle=Signal Transduct Target Ther：PD-1抑制剂Toripalimab（特瑞普利单抗）联合化疗二线治疗晚期EGFR突变NSCLC一线TKI进展后显示良好抗肿瘤疗效和可控安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d234293109ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278958, encodeId=a86f12e895891, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=J Immunother Cancer：中肿团队CAPTAIN研究证实国产PD-1抑制剂Camrelizumab（卡瑞利珠单抗）后线治疗复发或转移鼻咽癌疗效显著, objectType=article, longId=292765, objectId=7f53292e6591, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f53292e6591, replyNumber=0, likeNumber=89, createdTime=2021-12-27, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f53292e6591, moduleTitle=J Immunother Cancer：中肿团队CAPTAIN研究证实国产PD-1抑制剂Camrelizumab（卡瑞利珠单抗）后线治疗复发或转移鼻咽癌疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f53292e6591)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278957, encodeId=ea7a12e895760, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=Front Oncol：仑伐替尼（Lenvatinib）单药或联合PD-1抑制剂治疗中国晚期肝癌患者的疗效和安全性, objectType=article, longId=292159, objectId=2e392921592b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e392921592b, replyNumber=0, likeNumber=87, createdTime=2021-12-19, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e392921592b, moduleTitle=Front Oncol：仑伐替尼（Lenvatinib）单药或联合PD-1抑制剂治疗中国晚期肝癌患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e392921592b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278956, encodeId=6eb712e8956d1, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=Front Oncol：PD-1抑制剂nivolumab（纳武利尤单抗）治疗NSCLC患者的长期生存疗效和血液学标志物的探索, objectType=article, longId=291839, objectId=14f2291839cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14f2291839cd, replyNumber=0, likeNumber=58, createdTime=2021-12-16, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14f2291839cd, moduleTitle=Front Oncol：PD-1抑制剂nivolumab（纳武利尤单抗）治疗NSCLC患者的长期生存疗效和血液学标志物的探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14f2291839cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278955, encodeId=642612e89558b, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=Front Oncol：Lenvatinib（仑伐替尼）联合PD-1抑制剂一线治疗初始不可切除胆道癌(BTC)的疗效和安全性：单臂、开放标签II期临床研究, objectType=article, longId=221179, objectId=74cf2211e969, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74cf2211e969, replyNumber=0, likeNumber=89, createdTime=2021-11-29, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74cf2211e969, moduleTitle=Front Oncol：Lenvatinib（仑伐替尼）联合PD-1抑制剂一线治疗初始不可切除胆道癌(BTC)的疗效和安全性：单臂、开放标签II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74cf2211e969)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278954, encodeId=8e1912e89546f, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=Front Oncol：PD-1抑制剂camrelizumab（卡瑞利珠单抗）+XELOX化疗联合贝伐珠单抗或regorafenib（瑞戈非尼）作为一线治疗mCRC的有效性和安全性, objectType=article, longId=221101, objectId=e69e221101af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e69e221101af, replyNumber=0, likeNumber=68, createdTime=2021-11-28, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e69e221101af, moduleTitle=Front Oncol：PD-1抑制剂camrelizumab（卡瑞利珠单抗）+XELOX化疗联合贝伐珠单抗或regorafenib（瑞戈非尼）作为一线治疗mCRC的有效性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e69e221101af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278953, encodeId=824b12e895383, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=Front Oncol：包括抗血管抑制剂，PD-1抑制剂以及肝动脉灌注化疗（HAIC）的三联疗法治疗初始不可切除肝细胞癌时手术转化能力的回顾性评估, objectType=article, longId=220296, objectId=ddf8220296a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ddf8220296a1, replyNumber=0, likeNumber=82, createdTime=2021-11-15, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ddf8220296a1, moduleTitle=Front Oncol：包括抗血管抑制剂，PD-1抑制剂以及肝动脉灌注化疗（HAIC）的三联疗法治疗初始不可切除肝细胞癌时手术转化能力的回顾性评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ddf8220296a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278952, encodeId=707e12e895205, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=Front Oncol：一线化疗的基础上联合PD-1抑制剂可改善晚期胆道癌患者的预后, objectType=article, longId=219199, objectId=9d6e219199ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d6e219199ce, replyNumber=0, likeNumber=81, createdTime=2021-10-26, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d6e219199ce, moduleTitle=Front Oncol：一线化疗的基础上联合PD-1抑制剂可改善晚期胆道癌患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d6e219199ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278951, encodeId=a3a412e895132, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=Int J Cancer：甲状腺功能减退是PD-1抑制剂在肝癌中较好的抗肿瘤疗效预测因素。, objectType=article, longId=219038, objectId=74cc2190385f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74cc2190385f, replyNumber=0, likeNumber=79, createdTime=2021-10-23, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74cc2190385f, moduleTitle=Int J Cancer：甲状腺功能减退是PD-1抑制剂在肝癌中较好的抗肿瘤疗效预测因素。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74cc2190385f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278950, encodeId=e8a812e895099, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=Front Oncol：安罗替尼联合PD-1抑制剂治疗晚期实体肿瘤有效且毒性可控, objectType=article, longId=218379, objectId=64ef2183e9b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64ef2183e9b4, replyNumber=0, likeNumber=78, createdTime=2021-10-12, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64ef2183e9b4, moduleTitle=Front Oncol：安罗替尼联合PD-1抑制剂治疗晚期实体肿瘤有效且毒性可控, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=64ef2183e9b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278949, encodeId=bc5012e8949c5, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=Front Oncol：呋喹替尼+PD-1抑制剂 vs 瑞戈非尼+ PD-1抑制剂治疗难治性微卫星稳定的转移性结直肠癌患者的疗效, objectType=article, longId=218182, objectId=cf9921818260, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf9921818260, replyNumber=0, likeNumber=69, createdTime=2021-10-08, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf9921818260, moduleTitle=Front Oncol：呋喹替尼+PD-1抑制剂 vs 瑞戈非尼+ PD-1抑制剂治疗难治性微卫星稳定的转移性结直肠癌患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf9921818260)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278948, encodeId=c02112e89489d, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=尿路上皮癌治疗新方案！全球免疫辅助治疗PD-1抑制剂获批, objectType=article, longId=216314, objectId=dcfc2163140f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dcfc2163140f, replyNumber=0, likeNumber=67, createdTime=2021-08-27, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dcfc2163140f, moduleTitle=尿路上皮癌治疗新方案！全球免疫辅助治疗PD-1抑制剂获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dcfc2163140f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278947, encodeId=461512e894738, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=ASCO 2021: 摘要概览与展望 7| PD-1抑制剂Keytruda冲击胃癌一线疗法新进展！, objectType=article, longId=211864, objectId=907c211864e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=907c211864e9, replyNumber=0, likeNumber=82, createdTime=2021-05-28, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=907c211864e9, moduleTitle=ASCO 2021: 摘要概览与展望 7| PD-1抑制剂Keytruda冲击胃癌一线疗法新进展！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=907c211864e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278946, encodeId=569212e8946cd, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=Gastric Cancer: PD-1抑制剂治疗的微卫星稳定性胃癌患者少肌症的疗效分析, objectType=article, longId=207970, objectId=547c20e97000, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=547c20e97000, replyNumber=0, likeNumber=89, createdTime=2021-03-08, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=547c20e97000, moduleTitle=Gastric Cancer: PD-1抑制剂治疗的微卫星稳定性胃癌患者少肌症的疗效分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=547c20e97000)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278945, encodeId=04da12e894513, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=Nat Med：胰腺癌治疗新进展！CXCR4拮抗剂+PD-1抑制剂+化疗的三联疗法，初步试验中疾病控制率达77%, objectType=article, longId=194894, objectId=3a80194894a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a80194894a3, replyNumber=0, likeNumber=39, createdTime=2020-05-29, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a80194894a3, moduleTitle=Nat Med：胰腺癌治疗新进展！CXCR4拮抗剂+PD-1抑制剂+化疗的三联疗法，初步试验中疾病控制率达77%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a80194894a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278944, encodeId=c25d12e894418, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=Nat Med：CXCR4拮抗剂+PD-1抑制剂+化疗三联疗法治疗胰腺癌获突破, objectType=article, longId=194893, objectId=9c8d19489351, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c8d19489351, replyNumber=0, likeNumber=94, createdTime=2020-05-29, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c8d19489351, moduleTitle=Nat Med：CXCR4拮抗剂+PD-1抑制剂+化疗三联疗法治疗胰腺癌获突破, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c8d19489351)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278943, encodeId=e68512e8943a9, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=全新分析支持PD-1抑制剂dostarlimab在子宫内膜癌中的应用, objectType=article, longId=193027, objectId=5ab819302e68, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ab819302e68, replyNumber=0, likeNumber=62, createdTime=2020-04-28, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ab819302e68, moduleTitle=全新分析支持PD-1抑制剂dostarlimab在子宫内膜癌中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ab819302e68)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278942, encodeId=e1ce12e89426e, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=Lancet oncol：PD-1抑制剂Camrelizumab治疗晚期肝癌患者的疗效和安全性, objectType=article, longId=189092, objectId=e4de1890923b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4de1890923b, replyNumber=0, likeNumber=55, createdTime=2020-03-03, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4de1890923b, moduleTitle=Lancet oncol：PD-1抑制剂Camrelizumab治疗晚期肝癌患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4de1890923b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PD-1抑制剂

2020-05-29

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

J Immunother Cancer：PD-1抑制剂联合化疗新辅助治疗可切除食管鳞状细胞癌患者的疗效

2022-01-16

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

STTT：国内多中心研究ORIENT-4证实PD-1抑制剂sintilimab（信迪利单抗）对有复发/难治性结外NK/T细胞淋巴瘤（r/r ENKTL）患者有效且耐受性良好

2021-12-31

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

Signal Transduct Target Ther：PD-1抑制剂Toripalimab（特瑞普利单抗）联合化疗二线治疗晚期EGFR突变NSCLC一线TKI进展后显示良好抗肿瘤疗效和可控安全性

2021-12-31

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

J Immunother Cancer：中肿团队CAPTAIN研究证实国产PD-1抑制剂Camrelizumab（卡瑞利珠单抗）后线治疗复发或转移鼻咽癌疗效显著

2021-12-27

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

Front Oncol：仑伐替尼（Lenvatinib）单药或联合PD-1抑制剂治疗中国晚期肝癌患者的疗效和安全性

2021-12-19

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

Front Oncol：PD-1抑制剂nivolumab（纳武利尤单抗）治疗NSCLC患者的长期生存疗效和血液学标志物的探索

2021-12-16

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

Front Oncol：Lenvatinib（仑伐替尼）联合PD-1抑制剂一线治疗初始不可切除胆道癌(BTC)的疗效和安全性：单臂、开放标签II期临床研究

2021-11-29

仁医06 (审核中...)

前往app查看评论内容

#PD-1抑制剂#

Front Oncol：PD-1抑制剂camrelizumab（卡瑞利珠单抗）+XELOX化疗联合贝伐珠单抗或regorafenib（瑞戈非尼）作为一线治疗mCRC的有效性和安全性

2021-11-28

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

Front Oncol：包括抗血管抑制剂，PD-1抑制剂以及肝动脉灌注化疗（HAIC）的三联疗法治疗初始不可切除肝细胞癌时手术转化能力的回顾性评估

2021-11-15

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

Front Oncol：一线化疗的基础上联合PD-1抑制剂可改善晚期胆道癌患者的预后

2021-10-26

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

Int J Cancer：甲状腺功能减退是PD-1抑制剂在肝癌中较好的抗肿瘤疗效预测因素。

2021-10-23

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

Front Oncol：安罗替尼联合PD-1抑制剂治疗晚期实体肿瘤有效且毒性可控

2021-10-12

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

Front Oncol：呋喹替尼+PD-1抑制剂 vs 瑞戈非尼+ PD-1抑制剂治疗难治性微卫星稳定的转移性结直肠癌患者的疗效

2021-10-08

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

尿路上皮癌治疗新方案！全球免疫辅助治疗PD-1抑制剂获批

2021-08-27

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

ASCO 2021: 摘要概览与展望 7| PD-1抑制剂Keytruda冲击胃癌一线疗法新进展！

2021-05-28

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

Gastric Cancer: PD-1抑制剂治疗的微卫星稳定性胃癌患者少肌症的疗效分析

2021-03-08

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

Nat Med：胰腺癌治疗新进展！CXCR4拮抗剂+PD-1抑制剂+化疗的三联疗法，初步试验中疾病控制率达77%

2020-05-29

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

Nat Med：CXCR4拮抗剂+PD-1抑制剂+化疗三联疗法治疗胰腺癌获突破

2020-05-29

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

全新分析支持PD-1抑制剂dostarlimab在子宫内膜癌中的应用

2020-04-28

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

Lancet oncol：PD-1抑制剂Camrelizumab治疗晚期肝癌患者的疗效和安全性

2020-03-03

科室
- - 订阅+
  - 更多科室
工具
服务